ADVENTRX Pharmaceuticals (ANX) is a development-stage specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates for the treatment of cancer. The company seeks to improve the performance of existing drugs by addressing limitations associated principally with their safety and use.
The company’s lead product candidates, ANX-530 (vinorelbine injectable emulsion), or Exelbine™, and ANX-514 (docetaxel lyophilized emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs.
Vinorelbine and Docetaxel have been on the market for years, and both drugs have broad applications for the treatment of solid tumors such as non-small cell lung cancer, breast cancer, etc.
The company plans to submit a New Drug Application (NDA) for Exelbine in the fourth quarter of 2010. For ANX-514, the company is evaluating the data from bioequivalence study expects to meet with the FDA to discuss the results.
In this video, ADVENTRX’s CEO, Brian M. Culley, discusses the potential for his company.
ADVENTRX PHARMA (ANX): Free Stock Analysis Report
Zacks Investment Research
